Skip to main content
. 2015 Mar 19;6:38. doi: 10.3389/fendo.2015.00038

Figure 4.

Figure 4

PTHrP-1-34 treatment does not alter BV/TV in apical vertebra of FGFR3−/− mice: 3D reconstruction of the apical vertebra from treated FGFR3−/− mice were compared with the corresponding vertebra from FGFR3+/+ mice. Coronal 3D images (A–C) show reduced trabecular bone in the FGFR3−/− vertebrae (B,C) regardless of treatment, compared with the FGFR3+/+ vertebra (A). 3D reconstructions (D–F) show wedging of the apical vertebra in placebo treated [(E), N = 18] mice compared with that of PTHrP-1-34 treated mice [(F), N = 16] or FGFR3+/+ control [(D), N = 5]. Trabecular bone was segmented into three regions [(G) dotted lines] to quantify bone volume as a percentage of tissue volume (BV/TV). The middle segment was excluded and the outer segments were analyzed separately to capture the Concave and Convex sides of the apical vertebrae. Quantitative analysis confirmed a significant reduction in BV/TV in the L5 reference vertebra of FGFR3−/− mice treated with placebo (white bar) and PTHrP-1-34 (gray bar) compared with FGFR3+/+ (black bar) mice. Concave/convex asymmetry (E) was reflected in a lower BV/TV on the convex compared with concave aspect of the apical vertebrae, with no significant impact of PTHrP treatment. *p < 0.05 compared with FGFR3+/+; ε p < 0.05 compared with Concave aspect.